Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

IMV Inc IMVIQ


Primary Symbol: IMVIF

Healthcare Biotechnology
IMV Inc. is a Canada-based company. The Company has no business operations.


GREY:IMVIF - Post by User

IMV Inc > Thoughts on the updates today?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(5)
•••
Comment by Biotech010on Mar 17, 2021 8:51am
212 Views
Post# 32814943

RE:Thoughts on the updates today?

RE:Thoughts on the updates today?It was a smart move to have Andrew on the call, the director of business development.The last question on the Q&A was good, DPX goes beyond Ovarian DLBCL etc so there is room for lots of partners. They hope to realize a partnership in 2021. Obviously, there will be collab agreemnet with Merck on the phase 2b in DLBCL. We're going to hear on that trial in Q1.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities